Vitamin D Supplementation in Vitamin D Deficient Obese Children During Weight-loss Program

NCT ID: NCT02828228

Last Updated: 2016-07-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-02-29

Study Completion Date

2019-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Analyze the influence of vitamin D supplementation in obese children during weight-loss program on BMI, body composition and bone mineral density.
2. Analyze the influence of vitamin D supplementation on the risk profile of obesity-related complications, namely impaired tolerance of glucose, insulin resistance, dyslipidemia and arterial hypertension, in obese children participating in weight-loss program.
3. Analyze the prevalence of vitamin D deficiency among obese children.
4. Analyze the risk factors of vitamin D deficiency in obese children (age, gender, pubertal status).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will be conducted as a continuation and development of "6-10-14 for Health" program. The first phase of the program, financed by the municipality of Gdansk, was conducted in 2011-2013. The program comprised of screening and survey conducted among all 6-, 10- and 14-year-old children attending primary and grammar schools. A total of 18 162 children (including 7 448 6-year olds, 6 720 10-year olds and 3 994 14-year olds) were examined. A group of children with risk factors of civilization-related diseases (overweight and obesity defined according to BMI percentile charts. was identified on the basis of the screening. This group included 2 798 (16.32%) children, among them 9.17% of 6-years of age, 19.30% of 10-years and 20.48% of 14-years). All these children were qualified to intervention and education program. A total of 1 627 children qualified on the basis of screening eventually took part in the first edition of the program.

A total of 4 meetings with participating children and their caregivers were scheduled during the 12-month-long education and intervention program: at enrollment, and 3, 6 and 12 months thereafter. The meetings had form of individual consultations with various specialists. The first visit included complex medical examination, discussion on a health status of a child, interpretation of laboratory findings, and consultations with dietician, psychologist and physical education specialist. After consulting all the specialists involved in the program, individual protocol of health intervention was developed for every child. The objectives of the intervention included modification of diet, increasing health activity level and strengthening of health-seeking behaviors of child's family members. Adherence to the protocol and achieved results were evaluated during follow-up meetings with the specialists, and constituted the basis for development of individualized intervention plans for subsequent months.

The preliminary evaluation of the program effects was conducted in the group of 300 participants. The average percentile of BMI at enrollment to the program and after 12 months of participation amounted to 92.96 and 88.83, respectively. Participation in the program was reflected by a significant decrease in BMI percentile (p=0.0001), as well as by a significant drop off in fat mass content measured by bioelectrical impedance, from 39.0% to 31.4% (p=0.0001).

On the basis of these findings, the municipality of Gdansk decided to support the program for 2014-2016.

The experiment will follow a pattern of double blind randomized study. The enrolled subjects will be randomly assigned to one of the two groups:

Group 1 - weight-loss program for 52 weeks + vitamin D 1200 (IU) daily for 26 weeks Group 2 - weight-loss program for 52 weeks +placebo daily for 26 weeks

Visit I: enrollment:

* medical history, physical examination
* interpretation of laboratory findings (the tests conducted during screening + concentration of vitamin D),
* anthropometric evaluation and analysis of body composition (bioimpedance method)
* consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention
* Kasch Pulse Recovery Test
* determination of hs-C-reactive protein, Interleukin 6, chemerin and adiponectin concentrations in blood samples obtained during screening
* informing parents about the objectives and protocol of the study
* obtaining written informed consent for participation in the study
* randomization to GROUP I or II
* densitometry (DXA) - within one week after enrollment

Visit II: after 13 weeks:

* medical history, physical examination
* anthropometric evaluation and analysis of body composition (bioimpedance method)
* consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention

Within a week prior to Visit III - obtaining blood (ca. 5 ml) for laboratory testing (complete blood count, lipid profile, hs-C-reactive protein, oral glucose tolerance test, insulin, Interleukin 6, adiponectin and chemerin concentrations

Visit III: after 26 weeks:

* medical history, physical examination
* interpretation of laboratory findings
* anthropometric evaluation and analysis of body composition (bioimpedance method)
* consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention
* obtaining blood for laboratory testing
* termination of active compound/placebo administration

Visit IV: after 52 weeks:

* medical history, physical examination
* anthropometric evaluation and analysis of body composition (bioimpedance method)
* consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention
* densitometry (DXA) - within one week after terminating the study

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vitamin D 1200 IU

Supplementation with vitamin D (1200 IU) once a day for 26 weeks

Group Type EXPERIMENTAL

Vitamin D 1200 IU

Intervention Type DRUG

Vitamin D 1200 IU once a day for 26 weeks

Placebo

Placebo once a day for 26 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo once a day for 26 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin D 1200 IU

Vitamin D 1200 IU once a day for 26 weeks

Intervention Type DRUG

Placebo

placebo once a day for 26 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

cholecalciferol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* overweight (BMI between the 85th and 95th percentile) or obesity (BMI \> 95th percentile), identified on the basis of anthropometric parameters
* blood concentration of 25(OH)D3 \< 30 ng/ml
* written consent of legal guardians

Exclusion Criteria

* Chronic conditions (asthma or allergies, inflammatory diseases of connective tissue, gastrointestinal disorders, diseases of kidneys and liver, disorders of bone metabolism)
* Contraindications to administration of vitamin D
* Administration of any preparation containing vitamin D, calcium, or steroid hormones during 3 months preceding the study
Minimum Eligible Age

6 Years

Maximum Eligible Age

14 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nutricia Foundation

OTHER

Sponsor Role collaborator

University Clinical Centre, Gdansk

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Agnieszka Szlagatys-Sidorkiewicz, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University Clinical Centre, Gdansk

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

IUCCGdansk

Gdansk, Pomeranian Voivodeship, Poland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Poland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Magdalena Słominska-Frączek, MD,

Role: CONTACT

694844420

Agnieszka Jankowska, MD, PhD

Role: CONTACT

48606335246

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Agnieszka Szlagatys, MD, PhD

Role: primary

601622894

References

Explore related publications, articles, or registry entries linked to this study.

Szlagatys-Sidorkiewicz A, Brzezinski M, Jankowska A, Metelska P, Slominska-Fraczek M, Socha P. Long-term effects of vitamin D supplementation in vitamin D deficient obese children participating in an integrated weight-loss programme (a double-blind placebo-controlled study) - rationale for the study design. BMC Pediatr. 2017 Apr 4;17(1):97. doi: 10.1186/s12887-017-0851-7.

Reference Type DERIVED
PMID: 28376768 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

01/2016/UCK

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Vitamin D Treatment on Fatigue
NCT02022475 COMPLETED PHASE3
Vitamin D, Diet and Activity Study
NCT01240213 COMPLETED NA